The Current Ratio as of November 2024 (TTM) for Enanta Pharmaceuticals, Inc. (ENTA) is 4.92

According to Enanta Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.92. This represents a change of -19.11% compared to the average of 6.08 of the last 4 quarters.

Enanta Pharmaceuticals, Inc. (ENTA) Historical Current Ratio (quarterly & annually)

How has ENTA Current Ratio performed in the past?

The mean historical Current Ratio of Enanta Pharmaceuticals, Inc. over the last ten years is 17.46. The current 4.92 Current Ratio has changed 2.72% with respect to the historical average. Over the past ten years (40 quarters), ENTA's Current Ratio was at its highest in in the December 2016 quarter at 34.84. The Current Ratio was at its lowest in in the June 2024 quarter at 4.92.

Enanta Pharmaceuticals, Inc. (ENTA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Enanta Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Enanta Pharmaceuticals, Inc. (ENTA) Average Current Ratio

How has ENTA Current Ratio performed in the past?

The current Current Ratio of Enanta Pharmaceuticals, Inc. (ENTA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Enanta Pharmaceuticals, Inc. (ENTA) Current Ratio vs. Peers

How is ENTA’s Current Ratio compared to its peers?

Enanta Pharmaceuticals, Inc.’s Current Ratio is less than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Werewolf Therapeutics, Inc. (10.10), less than Ikena Oncology, Inc. (15.32), less than Stoke Therapeutics, Inc. (5.09), less than Crinetics Pharmaceuticals, Inc. (16.38), greater than Inhibrx Biosciences, Inc. (4.70), less than Merus N.V. (8.32), less than Lyell Immunopharma, Inc. (13.43), less than Kronos Bio, Inc. (8.32), less than Century Therapeutics, Inc. (10.39), less than Edgewise Therapeutics, Inc. (26.35), less than C4 Therapeutics, Inc. (6.31), less than Mineralys Therapeutics, Inc. (8.55), less than Cullinan Oncology, Inc. (24.46), less than Theseus Pharmaceuticals, Inc. (29.93), less than Revolution Medicines, Inc. (14.24),

Build a custom stock screener for Enanta Pharmaceuticals, Inc. (ENTA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enanta Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Enanta Pharmaceuticals, Inc. (ENTA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Enanta Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.